Escherichia coli: Development of Carbapenem Resistance During Therapy
Open Access
- 15 May 2005
- journal article
- case report
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 40 (10) , e84-e86
- https://doi.org/10.1086/429822
Abstract
A 76-year-old woman had recurrent urosepsis due to extended-spectrum β-lactamase-positive Escherichia coli. Imipenem resistance was detected after long-term imipenem-meropenem therapy. The carbapenem-hydrolyzing enzyme gene was identified as blaKPC-3. To our knowledge, this is the first documented case in which carbapenem-resistant E. coli emerged during therapy with imipenem and meropenem, and the first identification of the carbapenem-hydrolyzing enzyme in E. coli isolates.Keywords
This publication has 5 references indexed in Scilit:
- Outbreak of Klebsiella pneumoniae Producing a New Carbapenem-Hydrolyzing Class A β-Lactamase, KPC-3, in a New York Medical CenterAntimicrobial Agents and Chemotherapy, 2004
- Imipenem Resistance in a Salmonella Clinical Strain Due to Plasmid-Mediated Class A Carbapenemase KPC-2Antimicrobial Agents and Chemotherapy, 2003
- Plasmid-mediated, carbapenem-hydrolysing beta-lactamase, KPC-2, in Klebsiella pneumoniae isolatesJournal of Antimicrobial Chemotherapy, 2003
- Novel Carbapenem-Hydrolyzing β-Lactamase, KPC-1, from a Carbapenem-Resistant Strain ofKlebsiella pneumoniaeAntimicrobial Agents and Chemotherapy, 2001
- Carbapenem Resistance in Escherichia coli Associated with Plasmid-Determined CMY-4 β-Lactamase Production and Loss of an Outer Membrane ProteinAntimicrobial Agents and Chemotherapy, 1999